Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases

What this Trial Is About

Researchers are studying neurodegenerative diseases by using advanced 'omics' technologies to uncover genetic variants, proteins, and molecular pathways involved in these conditions. The goal is to better understand the biology behind neurodegeneration and to find new markers that can help diagnose, predict progression, and monitor response to therapies. At least 1,200 individuals with various neurodegenerative diseases will participate in this observational study. Participants will provide biological samples such as blood, saliva (if blood is not possible), and urine, collected during routine follow-up visits. These samples will be analyzed using genomic, transcriptomic, epigenomic, proteomic, and metabolic methods. DNA and other sample derivatives will be stored in biobanks and sent to specialized laboratories for comprehensive molecular analysis to identify genetic changes and their effects on disease mechanisms. During the study, participants will have regular outpatient visits where samples are collected as part of their usual care. Researchers will integrate clinical data with molecular findings to identify disease markers and track molecular changes over time. The primary outcome is to identify genetic, protein, and metabolic variants associated with neurodegenerative diseases over a 10-year period. No experimental treatments are involved, and the study focuses on observation and sample analysis.

Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases